MXPA05011110A - Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. - Google Patents

Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.

Info

Publication number
MXPA05011110A
MXPA05011110A MXPA05011110A MXPA05011110A MXPA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
prevention
treatment
meningococcal disease
novel immunogenic
Prior art date
Application number
MXPA05011110A
Other languages
English (en)
Inventor
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05011110A publication Critical patent/MXPA05011110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se relaciona a proteinas de Neisseria ORF2086, proteinas inmunogenicas de reaccion cruzada que pueden ser aisladas de cultivos de Neisseria o preparadas de modo recombinante, incluyendo porciones inmunogenicas de las mismas, equivalentes biologicos de las mismas, anticuerpos que se enlazan inmunoespecificamente a las secuencias de acido nucleico y foraneas que codifican a cada una de las foraneas, asi como al uso de las mismas en composiciones inmunogenicas que son eficaces contra la infeccion por Neisseria meningitidis del serogrupo B.
MXPA05011110A 2003-04-16 2004-04-16 Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. MXPA05011110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46316103P 2003-04-16 2003-04-16
PCT/US2004/011901 WO2004094596A2 (en) 2003-04-16 2004-04-16 Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Publications (1)

Publication Number Publication Date
MXPA05011110A true MXPA05011110A (es) 2006-01-24

Family

ID=33310752

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011110A MXPA05011110A (es) 2003-04-16 2004-04-16 Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.

Country Status (11)

Country Link
US (5) US20070253964A1 (es)
EP (1) EP1618185A4 (es)
JP (1) JP2006525330A (es)
KR (1) KR20060019515A (es)
CN (1) CN1867354A (es)
AU (2) AU2004233012A1 (es)
BR (1) BRPI0409459A (es)
CA (1) CA2522751A1 (es)
CO (1) CO5700785A2 (es)
MX (1) MXPA05011110A (es)
WO (1) WO2004094596A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
CN100473663C (zh) 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
ME01334B (me) 2005-04-08 2013-12-20 Wyeth Llc Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1943269A2 (en) * 2005-10-14 2008-07-16 Intercell AG Neisseria meningitidis antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP3705579A1 (en) 2006-07-27 2020-09-09 Wyeth LLC High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
EP2493499A1 (en) * 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
JP2013521770A (ja) * 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
JP6227407B2 (ja) * 2010-05-14 2017-11-08 バクスアルタ インコーポレイテッド Ｏｓｐａキメラおよびそのワクチンでの使用法
KR101609032B1 (ko) 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
PE20140173A1 (es) * 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
JP2015521595A (ja) 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
EP2964665B1 (en) * 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
SG11201606478YA (en) 2014-02-28 2016-09-29 Glaxosmithkline Biolog Sa Modified meningococcal fhbp polypeptides
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
GB202016604D0 (en) * 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
CN113372571A (zh) * 2021-07-05 2021-09-10 云南紫辰集团生物科技有限公司 黄腐酸钾干粉的生产工艺
CN114295845A (zh) * 2021-12-01 2022-04-08 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法降钙素原胶乳比浊检测试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466829A (en) * 1892-01-12 Carpet-stretcher
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
US7635486B1 (en) * 1998-02-03 2009-12-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant lipidated PsaA protein, methods of preparation and use
ES2304065T3 (es) * 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
JP4673974B2 (ja) * 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
US20070020622A1 (en) * 2001-09-14 2007-01-25 Invitrogen Corporation DNA Polymerases and mutants thereof
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
CN1867354A (zh) 2006-11-22
US20070082866A1 (en) 2007-04-12
JP2006525330A (ja) 2006-11-09
WO2004094596A2 (en) 2004-11-04
EP1618185A2 (en) 2006-01-25
US20070253964A1 (en) 2007-11-01
US20070082007A1 (en) 2007-04-12
US20090202593A1 (en) 2009-08-13
EP1618185A4 (en) 2009-05-27
US20070082006A1 (en) 2007-04-12
BRPI0409459A (pt) 2006-05-02
CO5700785A2 (es) 2006-11-30
KR20060019515A (ko) 2006-03-03
WO2004094596A8 (en) 2006-06-15
AU2004233012A1 (en) 2004-11-04
CA2522751A1 (en) 2004-11-04
AU2010200892A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
MA27699A1 (fr) Vaccin contre vhc
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
DE60028970D1 (de) An her2 bindende peptidverbindungen
TW200738877A (en) Immunostimulatory oligoribonucleotides
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
RU2007139915A (ru) Haemophilus influenzae типа в
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
WO2003105890A3 (en) VACCINE COMPOSITIONS
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
NZ595063A (en) Polypeptides from neisseria meningitidis
JP2008508859A5 (es)
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
EA201001322A1 (ru) Вакцины против хламидиоза
TW200514569A (en) Vaccine composition
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
IL169367A0 (en) Defensin proteins
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
MA27474A1 (fr) Vaccin
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
WO2005117956A3 (en) Neisserial vaccines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal